The company's GSP Neonatal Creatine Kinase-MM kit measures the CK-MM protein and is the first test to help in newborn screening for Duchenne Muscular Dystrophy.
The subsidiary is the Taiwan-based firm's first and potentially could provide it access to the genetic testing markets in Laos, Cambodia, Vietnam, and Indonesia.
The Lantern Project will screen for patients who may be suffering from Gaucher disease, Fabry disease, Pompe disease, MPS I, or ASMD, and offer confirmatory DNA testing.
The effort, sponsored by two therapeutics companies, is providing no-cost genetic testing and counseling for people with Duchenne who otherwise couldn't afford it.
AmCare Genomics said that it has a large network that would enable it to raise awareness about Genomic Vision's test for facioscapulohumeral muscular dystrophy.
